May 6th 2024
Significant findings included a 100% biochemical recurrence-free rate at 24 months post-surgery in patients with high-risk localized prostate cancer.
Pharma in Argentina: An Interview with Juan Pablo Bagó
December 7th 2014Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover from international markets in the coming years.